Biocon News

Pink Tax, is a commonly used term to describe the disparity in pricing of a product on the basis of gender-- where certain products are priced higher for women than for men.

Let’s read more about India’s first self-made entrepreneur and her story of how she challenged the patriarchy to build the revolutionary company.

Nikhil Kamath has also invited listeners and viewers of the podcast to have a say and cast their vote in choosing the cause that will receive this generous contribution. 

If you are one of the those aspiring to be a businessman, then you must be aware that success is the result of relentless pursuit, unwavering determination, and a willingness to overcome challenges. True success lies in pushing boundaries, embracing failure as a stepping stone to growth, and staying committed to continuous improvement. It requires resilience, perseverance, and a mindset that embraces change. Success is not an endpoint but a journey, shaped by passion, discipline, and a clear vision. It is a reflection of one's character, integrity, and ability to make a difference in the lives of others. And if you will read the story of Kiran Mazumdar-Shaw, the founder of Biocon Limited, her remarkable journey from a middle-class background to becoming one of India's most successful entrepreneurs, will surely inspire you.

According to the official website of Biocon, John Shaw served Biocon as the Vice Chairman and non executive director of the company.

A new scam of giving government approval to medicines has been exposed. In this connection, the CBI has arrested some officials of a drug authority of the Government of India. These officers used to approve drugs in exchange for bribes.

Karnataka CM Basavaraj Bommai on Thursday said that everyone should show restraint. Earlier, Biocon chief Kiran Majumdar Shaw had mentioned `growing religious divide` in her tweet. She had tweeted, "Karnataka has always forged inclusive economic development and we must not allow such communal exclusion."

Industry wants lower corporate tax rates to afford investment for expansion, she added. Shaw said the government wants more tax income to afford greater public sector spending and investment. Sitharaman will present the Union Budget 2022 today (February 1) at 11 Am in the Lok Sabha.

Mazumdar-Shaw tweeted on Saturday. She had expressed concern over shortage of COVID-19 vaccines. India has announced expansion of its COVID-19 vaccination drive.

Chairperson and managing director of Biocon Ltd Kiran Mazumdar-Shaw believes India could have a vaccine by June 2021. Mazumdar-Shaw said that delivering the vaccine to all Indians will be challenging. Biocon announced its September quarter earnings which fell from Rs 216 crore to Rs 169 crore in the year-ago quarter.

Biocon chairperson Kiran Mazumdar-Shaw on Monday (August 17) said that she has tested positive for coronavirus COVID-19. Mazumdar-Shaw said that she currently has mild symptoms of coronavirus. After Mazumdar-Shaw posted the tweet, several people took to Twitter to wish her speedy recovery.

The Bengaluru-headquartered biopharmaceuticals company said Q4FY20 revenue was up six per cent at Rs 1,644 crore.

Following the drop in the stock price, the company's market valuation went down by Rs 2,202 crore to Rs 37,608 crore.

Shares of Biocon on Monday surged as much as 14 percent in morning trade after the biotechnology major said it has received regulatory approval to market a biosimilar of cancer drug Herceptin in the United States.

While the demonetisation of Rs 500 and Rs 1000 have reportedly reduced even terror funding and corruption to a certain level, the move itself has been questioned by many.

Biotechnology major Biocon on Monday said it has appointed Suresh Subramanian as the Head of the company's branded formulations (India) business.

Government's move to relax FDI norms in sectors, including civil aviation, single-brand retail, defence and pharma, will help attract big investments and boost job creation, India Inc said on Monday.

Shares of biotechnology major Biocon today jumped by 4.75 percent after the company received approval from the Japanese health authority to sell bio-similar product 'Insulin Glargine' in the country.

Mazumdar-Shaw is one of the few vocal Indian industrialists on government policies and is the Chairman and Managing Director of India's biggest biotech company, Biocon.

Stocks of biotechnology major Biocon on Thursday surged over 5 percent after the company launched advanced novel therapy for the treatment of Hepatitis C at low cost.